- List
- By Topic
- On Map
- Search Details

nasopharyngeal cancer | "Nasopharyngeal Neoplasms"
Need help? See RSS Feeds
Choose a feed type:

nasopharyngeal cancer | "Nasopharyngeal Neoplasms" (334 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02611960 | Recruiting | Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
230 | All | 18 Years and older (Adult, Senior) | NCT02611960 | 3475-122 MK-3475-122 |
April 18, 2016 | March 5, 2020 | March 5, 2020 | November 23, 2015 | April 20, 2018 |
|
||
2 | NCT00747799 | Completed | Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) |
|
|
Interventional | Phase 2 |
|
Other |
|
|
54 | All | 18 Years and older (Adult, Senior) | NCT00747799 | BAY43-9006-2008003 | January 2009 | May 2011 | November 2011 | September 5, 2008 | December 10, 2013 |
|
||
3 | NCT00078494 | Completed | Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer |
|
|
Interventional | Phase 1 |
|
NIH |
|
99 | All | Child, Adult, Senior | NCT00078494 | 040118 04-CC-0118 |
February 2004 | May 2006 | March 1, 2004 | March 4, 2008 |
|
||||
4 | NCT00577057 | Unknown † | Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
798 | All | 18 Years to 70 Years (Adult, Senior) | NCT00577057 | HKEC-2006-120 HARECCTR0500062 NPC-0501 |
September 2006 | August 2013 | December 19, 2007 | August 22, 2013 |
|
|||
5 | NCT00123864 | Completed | Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
25 | All | 18 Years and older (Adult, Senior) | NCT00123864 | HN-4-0003 | January 2000 | July 26, 2005 | February 9, 2010 |
|
||||
6 | NCT02250599 | Unknown † | Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
80 | All | 18 Years and older (Adult, Senior) | NCT02250599 | ML29153 | August 2014 | April 2016 | December 2016 | September 26, 2014 | December 30, 2015 |
|
||
7 | NCT01528618 | Unknown † | Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 3 |
|
Other |
|
|
362 | All | 18 Years and older (Adult, Senior) | NCT01528618 | GEM20110714 | October 2015 | June 2016 | June 2017 | February 8, 2012 | January 12, 2016 |
|
||
8 | NCT02360501 | Completed | Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
50 | All | 18 Years to 75 Years (Adult, Senior) | NCT02360501 | DCX in NPC | January 2008 | March 2016 | April 2016 | February 10, 2015 | April 20, 2016 |
|
||
9 | NCT00630149 | Completed | Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
35 | All | 18 Years and older (Adult, Senior) | NCT00630149 | H3E-GH-0034 | November 2007 | November 2011 | January 2012 | March 6, 2008 | February 16, 2012 |
|
||
10 | NCT03180476 | Recruiting | Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
24 | All | 18 Years to 75 Years (Adult, Senior) | NCT03180476 | Ahead-NC-201701 | April 1, 2017 | December 1, 2018 | April 1, 2019 | June 8, 2017 | June 14, 2017 |
|
||
11 | NCT02627807 | Recruiting | Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma |
|
|
Interventional | Not Applicable |
|
Other |
|
|
378 | All | 18 Years to 65 Years (Adult) | NCT02627807 | 2012011 | December 2015 | December 2020 | December 2022 | December 11, 2015 | January 10, 2017 |
|
||
12 | NCT03427827 | Not yet recruiting | Adjuvant PD-1 Antibody in Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 3 |
|
Other |
|
|
400 | All | 18 Years to 65 Years (Adult) | NCT03427827 | B2017-097-01 | June 2018 | February 2022 | February 2024 | February 9, 2018 | April 24, 2018 | |||
13 | NCT01735409 | Unknown † | Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
69 | All | 18 Years and older (Adult, Senior) | NCT01735409 | ABXDDP20101224 | ABX-DDP-Dose | November 2012 | March 2014 | June 2014 | November 28, 2012 | January 28, 2014 |
|
|
14 | NCT02874651 | Recruiting | ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy |
|
|
Interventional | Phase 2 |
|
Other |
|
|
103 | All | 18 Years to 70 Years (Adult, Senior) | NCT02874651 | Ahead-N301 | ADVANCE | October 2016 | June 2021 | June 2021 | August 22, 2016 | November 1, 2016 |
|
|
15 | NCT02269943 | Completed | Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
36 | All | 18 Years and older (Adult, Senior) | NCT02269943 | CC-486-NPC-001 2014-001745-25 |
February 13, 2015 | April 20, 2017 | April 20, 2017 | October 21, 2014 | April 17, 2018 |
|
||
16 | NCT00436800 | Completed | Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
41 | All | 18 Years and older (Adult, Senior) | NCT00436800 | L_9281 | March 2005 | October 2008 | October 2008 | February 19, 2007 | September 18, 2009 |
|
||
17 | NCT00563927 | Unknown † | Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) |
|
|
Interventional | Not Applicable |
|
Other |
|
|
340 | All | up to 70 Years (Child, Adult, Senior) | NCT00563927 | L/M-77 TO PYH08/79 HARECCTR0500023 NPC99-01 |
March 1999 | October 2009 | November 26, 2007 | July 7, 2010 |
|
|||
18 | NCT00565448 | Completed Has Results |
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
75 | All | 1 Month to 21 Years (Child, Adult) | NCT00565448 | EFC10339 2007-001211-33 |
November 2007 | March 2009 | January 2012 | November 30, 2007 | July 30, 2015 | March 25, 2010 |
|
|
19 | NCT00563862 | Terminated | Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0) |
|
|
Interventional | Not Applicable |
|
Other |
|
|
465 | All | up to 70 Years (Child, Adult, Senior) | NCT00563862 | L/M-78 to PYH 08/79 HARECCTR0500024 NPC99-02 |
July 1999 | June 2007 | November 26, 2007 | June 16, 2011 |
|
|||
20 | NCT00188877 | Active, not recruiting | Intensity Modulated Radiation Therapy for Head and Neck Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
44 | All | 18 Years to 70 Years (Adult, Senior) | NCT00188877 | UHN REB 03-0158-C | June 2003 | June 2008 | June 2018 | September 16, 2005 | September 25, 2017 |
|
||
21 | NCT02948699 | Recruiting | A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients |
|
|
Interventional | Phase 4 |
|
Other |
|
|
100 | All | 18 Years to 65 Years (Adult) | NCT02948699 | NPC-NUTR-2016 | November 2016 | September 2019 | October 2019 | October 28, 2016 | April 14, 2017 |
|
||
22 | NCT03093649 | Not yet recruiting | Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma |
|
|
Interventional | Not Applicable |
|
Other |
|
|
320 | All | 18 Years and older (Adult, Senior) | NCT03093649 | 2017-FXY-003-放疗科 | July 2017 | May 2019 | May 2019 | March 28, 2017 | March 28, 2017 |
|
||
23 | NCT01797900 | Completed | The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT |
|
|
Interventional | Phase 2 |
|
Other |
|
|
130 | All | 18 Years to 70 Years (Adult, Senior) | NCT01797900 | CH-HN-002 | March 2013 | September 2014 | September 2014 | February 25, 2013 | September 10, 2014 |
|
||
24 | NCT00436293 | Completed | Taxotere + Cisplatin in Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
61 | All | 18 Years and older (Adult, Senior) | NCT00436293 | XRP6976F_6002 | December 2002 | March 2010 | March 2010 | February 19, 2007 | November 17, 2010 |
|
||
25 | NCT00363831 | Unknown † | Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
42 | All | 18 Years to 75 Years (Adult, Senior) | NCT00363831 | L_9863 | July 2006 | December 2009 | August 15, 2006 | July 28, 2010 |
|
|||
26 | NCT02735317 | Unknown † | Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT |
|
|
Interventional | Phase 2 |
|
Other |
|
|
90 | All | 18 Years to 65 Years (Adult) | NCT02735317 | B2015-074-01 | April 2016 | June 2017 | June 2017 | April 12, 2016 | April 12, 2016 |
|
||
27 | NCT02945878 | Recruiting | Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma |
|
Observational |
|
Other |
|
|
90 | All | 18 Years to 70 Years (Adult, Senior) | NCT02945878 | NPC-MUCO | October 2016 | March 2018 | May 2018 | October 26, 2016 | June 28, 2017 |
|
||||
28 | NCT02729324 | Unknown † | Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT |
|
|
Interventional | Phase 2 |
|
Other |
|
|
136 | All | 18 Years to 65 Years (Adult) | NCT02729324 | B2015-071-01 | April 2016 | June 2017 | June 2017 | April 6, 2016 | April 6, 2016 |
|
||
29 | NCT02505139 | Completed | The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients |
|
|
Observational |
|
Other |
|
|
166 | All | 18 Years to 65 Years (Adult) | NCT02505139 | SYSUCCCTC | December 2014 | July 2016 | August 2016 | July 22, 2015 | August 29, 2016 | ||||
30 | NCT01257100 | Completed | Environmental and Genetic Determinants of NPC |
|
Observational |
|
NIH / Other |
|
|
3500 | All | 21 Years to 100 Years (Adult, Senior) | NCT01257100 | 999911040 11-C-N040 |
December 8, 2010 | December 9, 2010 | April 5, 2018 |
|
||||||
31 | NCT02444949 | Unknown † | A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 3 |
|
Other |
|
|
72 | All | 18 Years to 70 Years (Adult, Senior) | NCT02444949 | CTGU1501 | June 2014 | June 2017 | June 2017 | May 15, 2015 | May 15, 2015 | |||
32 | NCT02915445 | Recruiting | EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer |
|
|
Interventional | Phase 1 |
|
Other |
|
|
30 | All | 18 Years to 65 Years (Adult) | NCT02915445 | SKLB-083 | July 2016 | July 2017 | July 2019 | September 27, 2016 | September 27, 2016 |
|
||
33 | NCT02456506 | Recruiting | Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma. |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
142 | All | 18 Years to 65 Years (Adult) | NCT02456506 | SYSU5010 | June 2015 | June 2018 | June 2019 | May 28, 2015 | May 25, 2016 |
|
||
34 | NCT02211677 | Recruiting | Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma |
|
Observational |
|
Other |
|
|
500 | All | 18 Years to 75 Years (Adult, Senior) | NCT02211677 | B2014-002-01 | August 2014 | December 2019 | December 2024 | August 7, 2014 | July 13, 2017 |
|
||||
35 | NCT01074021 | Unknown † | Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer |
|
|
Interventional | Phase 3 |
|
Other |
|
|
480 | All | 18 Years to 70 Years (Adult, Senior) | NCT01074021 | BT-CT-001 | October 2009 | May 2016 | August 2016 | February 24, 2010 | October 30, 2015 |
|
||
36 | NCT02149641 | Completed | Parotid-sparing IMRT for Nasopharyngeal Cancer |
|
|
Observational |
|
Other |
|
|
42 | All | 16 Years and older (Child, Adult, Senior) | NCT02149641 | CCR2608 | February 2006 | April 2011 | April 2012 | May 29, 2014 | May 29, 2014 |
|
|||
37 | NCT02116231 | Not yet recruiting | The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
80 | All | 18 Years to 70 Years (Adult, Senior) | NCT02116231 | CHGX20140402 | April 2014 | May 2017 | May 2018 | April 16, 2014 | April 16, 2014 |
|
||
38 | NCT02608073 | Completed | A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
45 | All | 18 Years to 75 Years (Adult, Senior) | NCT02608073 | ML18123 | November 2004 | November 2009 | November 2009 | November 18, 2015 | March 2, 2016 |
|
||
39 | NCT00828386 | Terminated | Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers |
|
|
Interventional | Phase 3 |
|
Other |
|
|
83 | All | 18 Years to 70 Years (Adult, Senior) | NCT00828386 | GORTEC-NPC2006 | GORTEC-NPC2006 | January 2009 | August 2015 | August 2015 | January 23, 2009 | March 24, 2015 |
|
|
40 | NCT00342147 | Active, not recruiting | Family Study of Head and Neck Cancers in Taiwan |
|
Observational |
|
NIH |
|
|
3795 | All | 18 Years to 99 Years (Adult, Senior) | NCT00342147 | 999995046 OH95-C-N046 |
November 7, 1995 | June 21, 2006 | April 5, 2018 |
|
||||||
41 | NCT03282617 | Recruiting | Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 1 |
|
Other |
|
|
55 | All | 18 Years to 99 Years (Adult, Senior) | NCT03282617 | NP01/03/16 | August 14, 2017 | August 14, 2019 | August 14, 2020 | September 14, 2017 | September 14, 2017 |
|
||
42 | NCT02875613 | Active, not recruiting | Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
39 | All | 18 Years and older (Adult, Senior) | NCT02875613 | 160114 | September 2016 | September 2019 | September 2020 | August 23, 2016 | April 17, 2018 |
|
||
43 | NCT01312311 | Unknown † | Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
51 | All | 18 Years and older (Adult, Senior) | NCT01312311 | 2006-07-005 | July 2006 | May 2011 | March 10, 2011 | March 10, 2011 |
|
|||
44 | NCT03007836 | Recruiting | High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 30 Years to 60 Years (Adult) | NCT03007836 | HANK-nasopharynx | December 2016 | December 2017 | December 2019 | January 2, 2017 | January 4, 2017 |
|
||
45 | NCT00439426 | Completed | A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer. |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
25 | All | 18 Years to 75 Years (Adult, Senior) | NCT00439426 | ML20508 | April 2007 | September 2009 | September 2009 | February 23, 2007 | November 2, 2016 |
|
||
46 | NCT00941538 | Recruiting | Screening for Nasopharyngeal Carcinoma in High Risk Populations |
|
Observational |
|
Other |
|
|
30000 | All | 30 Years to 59 Years (Adult) | NCT00941538 | No.2006BAI02A11 | June 2009 | July 2012 | July 2019 | July 17, 2009 | July 23, 2009 |
|
||||
47 | NCT00173836 | Completed | Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount |
|
Observational |
|
Other |
|
122 | All | 20 Years and older (Adult, Senior) | NCT00173836 | Yeun-Chung Chang NSC 92-2218-E-227-001 |
August 2003 | August 2006 | August 2006 | September 15, 2005 | September 9, 2009 |
|
|||||
48 | NCT00305734 | Completed | Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT00305734 | NCI-2012-02690 SWOG-S0506 U10CA032102 CDR0000462635 |
August 2006 | July 2007 | March 22, 2006 | January 25, 2013 |
|
|||
49 | NCT03175939 | Completed | Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
263 | All | 18 Years to 75 Years (Adult, Senior) | NCT03175939 | NPC9801 | April 1, 1998 | December 31, 2008 | December 31, 2014 | June 5, 2017 | June 5, 2017 | |||
50 | NCT00603915 | Completed Has Results |
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
20 | All | 18 Years and older (Adult, Senior) | NCT00603915 | NPC-774 | June 2006 | December 2010 | April 2011 | January 29, 2008 | October 10, 2011 | August 10, 2011 |
|
† Study has passed its completion date and status has not been verified in more than two years.